Schrdinger, Inc. (SDGR) said Monday it has entered into a multi-year discovery collaboration with Bristol Myers Squibb Co. (BMY) to discover, develop, and commercialize therapeutics in multiple disease areas.
Under the collaboration, Schrdinger's will combine its physics-based computational platform and drug discovery capabilities with Bristol Myers Squibb's expertise in development and commercialization to advance small molecule therapeutics for targets in oncology, immunology, and neurological disorders.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com